Vaxcyte shares surge after pneumococcal vaccine meets Phase 3 trial goals

Statements (5)

1. ▲ Bullish

   Vaxcyte shares surged 35% after its experimental pneumococcal vaccine VAX-31 met key endpoints in a Phase 3 trial with adults

   endpoints.newsOct 5, 2026 15:06 UTCHigh importance
2. ▲ Bullish

   Vaxcyte stock rose after its experimental pneumococcal vaccine proved it is not inferior to marketed shots from Pfizer and Merck

   investors.comOct 5, 2026 13:18 UTCHigh importance
3. ▲ Bullish

   Vaxcyte's pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial

   statnews.comOct 5, 2026 13:10 UTC
4. ▲ Bullish

   Vaxcyte's experimental pneumococcal vaccine hit the primary endpoints in a Phase 3 clinical trial

   statnews.comOct 5, 2026 12:19 UTC
5. ▲ Bullish

   Vaxcyte shares surge as pneumococcal vaccine meets main trial goals

   reuters.comOct 5, 2026 10:37 UTC